Tasmanian devil facial tumor disease: Insights into reduced tumor surveillance from an unusual malignancy

International Journal of Cancer

Volumn 127, Issue 7, 2010, Pages 1637-1642

  O'Neill, Iain D ^a  

^a Centre d'Affaires Poincare   (France)

Author keywords

Allograft; Devil facial tumor disease; Immune evasion; Reduced MHC diversity; Tasmanian devil

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; PROTEIN S 100; VIMENTIN;

ANIMAL DISEASE; ANIMAL VENEREAL TUMOR; ANTIGEN EXPRESSION; AUSTRALIA; BREAST CARCINOMA; CADAVER DONOR; CANCER EPIDEMIOLOGY; CANCER GRAFT; CANCER INVASION; CELL LINEAGE; CELL MIGRATION; CELLULAR IMMUNITY; CHORIOCARCINOMA; CHROMOSOME REARRANGEMENT; DESMOSOME; DISEASE TRANSMISSION; ELECTRON MICROSCOPY; FACE CANCER; GRAFT RECIPIENT; GRAFT REJECTION; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KARYOTYPING; LEUKEMIA; LUNG CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOMA; MAJOR HISTOCOMPATIBILITY COMPLEX; MARSUPIAL; METASTASIS; MICROCHIMERISM; MORTALITY; MOUTH TUMOR; NONHUMAN; ORAL SEXUAL CONTACT; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SARCOPHILUS HARRISI; SOCIAL INTERACTION; VERTICAL TRANSMISSION; WORLD HEALTH ORGANIZATION; X CHROMOSOME; Y CHROMOSOME; ANIMAL; ARTICLE; CELL NUCLEUS; CYTOPLASM; FACE TUMOR; HISTOLOGY; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CELL NUCLEUS; CYTOPLASM; DISEASE TRANSMISSION, INFECTIOUS; FACIAL NEOPLASMS; HUMANS; MARSUPIALIA; MOUTH NEOPLASMS; TASMANIA;

EID: 77956591358     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25374     Document Type: Review

References (65)

1. Hawkins C, Baars C, Hesterman H, Hocking GJ, Jones ME, Lazenby B, Mann D, Mooney N, Pemberton D, Pyecroft S, Restani M, Wiersma J. Emerging disease and population decline of an island endemic, the Tasmanian devil Sarcophilus harrissii. Biol Conserv 2006;131:307-24.
2. McCallum H. Tasmanian devil facial tumour disease: lessons for conservation biology. Trends Ecol Evol 2008;23:631-7.
3. Lachish S, McCallum H, Jones M. Demography, disease and the devil: life-history changes in a disease-affected population of Tasmanian devils (Sarcophilus harrisii). J Anim Ecol 2009;78:427-36.
4. McCallum H, Jones M. To lose both would look like carelessness: Tasmanian devil facial tumor disease. PLoS Biol 2006;4:e342.
5. Jones ME, Cockburn A, Hamede R, Hawkins C, Hesterman H, Lachish S, Mann D, McCallum H, Pemberton D. Life-history change in disease-ravaged Tasmanian devil populations. Proc Natl Acad Sci USA 2008;105:10023-7.
6. Siddle HV, Kreiss A, Eldridge MD, Noonan E, Clarke CJ, Pyecroft S, Woods GM, Belov K. Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proc Natl Acad Sci USA 2007;104:16221-26.
7. Canfield PJ, Cunningham AA. Disease and mortality in Australasian marsupials held at London-Zoo, 1872-1972. J Zoo Wildlife Med 1993;24:158-67.
8. Griner LA. Neoplasms in Tasmanian devils. J Natl Cancer Inst 1979;62:589-95.
9. Canfield PJ, Hartley WJ, Reddacliff GL. Spontaneous proliferations in Australian marsupials: a survey and review. II. Dasyurids and Bandicoots. J Comp Pathol 1990;103:147-58.
10. Loh R, Bergfeld J, Hayes D, O'Hara A, Pyecroft S, Raidal S, Sharpe R. The pathology of Devil Facial Tumour Disease (DFTD) in Tasmanian Devils (Sarcophilus harrissii). Vet Pathol 2006;43:890-5.
11. Hamede R, McCallum HI, Jones ME. Seasonal, demographic and density-related patterns of contact between Tasmanian devils: implications for transmission of Devil Facial Tumour Disease. Aust Ecol 2008;33:614-22.
12. Obendorf DL, McGlashan ND. Research priorities in the Tasmanian devil facial tumour debate. Eur J Oncol 2008;13:229-38.
13. Save the Tasmanian devil: Tasmanian devil facial tumour disease. Available at: http://www.tassiedevil.com.au/disease.html. Accessed 31 December 2009.
14. Pyecroft SB, Pearse A-M, Loh R, Swift K, Belov K, Fox N, Noonan E, Hayes D, Hyatt A, Wang L, Boyle D, Church J, et al. Towards a case definition for devil facial tumour disease: what is it? Eco Health 2007;4:346-51.
15. Loh R, Hayes D, Mahjoor A, O'Hara A, Pyecroft S, Raidal S. The Immunohistochemical characterisation of Devil Facial Tumour Disease (DFTD) in Tasmanian Devils (Sarcophilus harrissii). Vet Pathol 2006;43:896-903. (Pubitemid 44785962)
16. Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, Obendorf D, Conlan C, Bahlo M, Blizzard CA, Pyecroft S, Kreiss A, et al. The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally transmissible cancer. Science 2010;327:84-7.
17. Solcia EG, Klöppel G, Sobin LH, eds. Histological typing of endocrine tumours. WHO international histological classification of tumors, 2nd edn. Berlin: Springer, 2000.
18. Kusafuka K, Asano R, Kamijo T, Iida Y, Onitsuka T, Kameya T, Nakajima T. Large cell neuroendocrine carcinoma of the tongue base: case report of an unusual location with immunohistochemical analysis. Int J Oral Maxillofac Surg 2009;38:296-9.
19. Radfar L, Fatahzadeh M. Neuroendocrine carcinoma of the oral cavity: a case report and review of the literature. Gen Dent 2008;56:714-8.
20. Salama AR, Jham BC, Papadimitriou JC, Scheper MA. Metastatic neuroendocrine carcinomas to the head and neck: report of 4 cases and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;108:242-7.
21. Pearse A-M, Swift K. Transmission of devil facial-tumour disease. Nature 2006;439:549.
22. Montali RJ, Bush M, Cromie R, Holland SM, Maslow JN, Worley M, Witebsky FG, Phillips TM. Primary Mycobacterium avium complex infections correlate with lowered cellular immune reactivity in Matschie's tree kangaroos (Dendrolagus matschiei). J Infect Dis 1998;178:1719-25.
23. Stone WH, Brunn DA, Foster EB, Manis GS, Hoffman ES, Saphire DG, VandeBerg JL, Infante AJ. Absence of a significant mixed lymphocyte reaction in a marsupial (Monodelphis domestica). Lab Anim Sci 1998;48:184-9.
24. Siddle HV, Sanderson C, Belov K. Characterization of major histocompatibility complex class I and class II genes from the Tasmanian devil (Sarcophilus harrisii). Immunogenetics 2007;59:753-60.
25. Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM. Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev Comp Immunol 2008;32:544-53.
26. Kreiss A, Wells B, Woods GM. The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Vet Immunol Immunopathol 2009;130:135-7.
27. Cohen D. The canine transmissible venereal tumor: a unique result of tumor progression. Adv Cancer Res 1985;43:75-112.
28. Murchison EP. Clonally transmissible cancers in dogs and Tasmanian devils. Oncogene 2009;27:S19-S30.
29. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA. Clonal origin and evolution of a transmissible cancer. Cell 2006;126:477-87.
30. Rebbeck CA, Thomas R, Breen M, Leroi AM, Burt A. Origins and evolution of a transmissible cancer. Evolution 2009;63:2340-49.
31. Cohen D, Shalev A, Krup M. Lack of beta 2-microglobulin on the surface of canine transmissible venereal tumor cells. J Natl Cancer Inst 1984;72:395-401.
32. Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 2002;87:19-27. (Pubitemid 34621428)
33. Yang TJ, Chandler JP, Dunne-Anway S. Growth stage dependent expression of MHC antigens on the canine transmissible venereal sarcoma. Br J Cancer 1987;55:131-4.
34. Mizuno S, Fujinaga T, Hagio M. Role of lymphocytes in spontaneous regression of experimentally transplanted canine transmissible venereal sarcoma. J Vet Med Sci 1994;56:15-20.
35. Pérez J, Day MJ, Mozos E. Immunohistochemical study of the local inflammatory infiltrate in spontaneous canine transmissible venereal tumour at different stages of growth. Vet Immunol Immunopathol 1998;64:133-47.
36. Cooper HL, Mackay CM, Banfield WG. Chromosome studies of a contagious reticulum cell sarcoma of the Syrian hamster. J Natl Cancer Inst 1964;33:691-706.
37. O'Brien SJ, Roelke ME, Marker L, Newman A, Winkler CA, Meltzer D, Colly L, Evermann JF, Bush M, Wildt DE. Genetic evidence for species vulnerability in the cheetah. Science 1985;227:1428-34.
38. Sanjayan MA, Crooks K, Zegers G, Foran D. Genetic variation and the immune response in natural populations of pocket gophers. Conserv Biol 1996;10:1519-27.
39. Gandhi MJ, Strong DM. Donor derived malignancy following transplantation: a review. Cell Tissue Bank 2007;8:267-86.
40. Buell JF, Beebe TM, Trofe J, Gross TG, Alloway RR, Hanaway MJ, Woodle ES. Donor transmitted malignancies. Ann Transplant 2004;9:53-6.
41. Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation 2002;74:358-62.
42. Penn I. Transmission of cancer from organ donors. Ann Transplant 1997;2:7-12.
43. Baehner R, Magrane G, Balassanian R, Chang C, Millward C, Wakil AE, Osorio RW, Waldman FM. Donor origin of neuroendocrine carcinoma in 2 transplant patients determined by molecular cytogenetics. Hum Pathol 2000;31:1425-9.
44. Foltys D, Linkermann A, Heumann A, Hoppe-Lotichius M, Heise M, Schad A, Schneider J, Bender K, Schmid M, Mauer D, Peixoto N, Otto G. Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report. Transplant Proc 2009;41:2639-42.
45. Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of successful pregnancy. Hum Reprod Update 2003;9:347-57.
46. Dawe GS, Tan XW, Xiao ZC. Cell migration from baby to mother. Cell Adh Migr 2007;1:19-27.
47. Johnson KL, Bianchi DW. Fetal cells in maternal tissue following pregnancy: what are the consequences? Hum Reprod Update 2004;10:497-502.
48. Sawicki JA. Fetal microchimerism and cancer. Cancer Res 2008;68:9567-9.
49. Shih IeM. Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets. Lancet Oncol 2007;8:642-50.
50. Small W, Jr, Lurain JR, Shetty RM, Huang CF, Applegate GL, Brand WN. Gestational trophoblastic disease metastatic to the brain. Radiology 1996;200:277-80.
51. Sierra-Bergua B, Sánchez-Marteles M, Cabrerizo-García JL, Sanjoaquin-Conde I. Choriocarcinoma with pulmonary and cerebral metastases. Singapore Med J 2008;49:e286-8.
52. Picone O, Castaigne V, Ede C, Fernandez H. Cerebral metastases of a choriocarcinoma during pregnancy. Obstet Gynecol 2003;102:1380-3.
53. Avril MF, Mathieu A, Kalifa C, Caillou C. Infantile choriocarcinoma with cutaneous tumours. An additional case and review of the literature. J Am Acad Dermatol 1986;14:918-27. (Pubitemid 16036836)
54. Heath JA, Tiedemann K. Successful management of neonatal choriocarcinoma. Med Pediatr Oncol 2001;36:497-9.
55. McNally OM, Tran M, Fortune D, Quinn MA. Successful treatment of mother and baby with metastatic choriocarcinoma. Int J Gynecol Cancer 2002;12:394-8.
56. Kishkurno S, Ishida A, Takahashi Y, Arai H, Nakajima W, Abe T, Takada G. A case of neonatal choriocarcinoma. Am J Perinatol 1997;14:79-82.
57. Liu J, Guo L. Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature. Gynecol Oncol 2006;103:1147-51.
58. Andreitchouk AE, Takahashi O, Kodama H, Morita M, Sankawa T, Saito K, Enomoto K, Tanaka T. Choriocarcinoma in infant and mother: a case report. J Obstet Gynaecol Res 1996;22:585-8.
59. Picton SV, Bose-Haider B, Lendon M, Hancock BW, Campbell RH. Simultaneous choriocarcinoma in mother and newborn infant. Med Pediatr Oncol 1995;25475-8.
60. Lefebvre S, Moreau P, Dausset J, Carosella ED, Paul P. Downregulation of HLA class I gene transcription in choriocarcinoma cells is controlled by the proximal promoter element and can be reversed by CIITA. Placenta 1999;20:293-301.
61. Murphy SP, Choi JC, Holtz R. Regulation of major histocompatibility complex class II gene expression in trophoblast cells. Reprod Biol Endocrinol 2004;2:52.
62. Alexander A, Samlowski WE, Grossman D, Bruggers CS, Harris RM, Zone JJ, Noyes RD, Bowen GM, Leachman SA. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. J Clin Oncol 2003;21:2179-86.
63. Dessolle L, Dalmon C, Roche B, Daraï E. [Placental metastases from maternal malignancies: review of the literature]. J Gynecol Obstet Biol Reprod (Paris) 2007;36:344-53.
64. Donegan WL. Cancer and pregnancy. CA Cancer J Clin 1983;33:194-214.
65. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist 2002;7:279-87.